



OPEN ACCESS

EDITED AND REVIEWED BY
Michael P. Lisanti,
University of Salford, United Kingdom

*CORRESPONDENCE

Nobu Oshima
✉ noshima@kuhp.kyoto-u.ac.jp

RECEIVED 12 February 2025

ACCEPTED 21 February 2025

PUBLISHED 05 March 2025

CITATION

Oshima N, Aisu Y, Masuo A, Takakusagi Y and Kawai T (2025) Editorial: Targeting and monitoring cancer metabolism: novel theranostics for colorectal cancer. *Front. Oncol.* 15:1575563. doi: 10.3389/fonc.2025.1575563

COPYRIGHT

© 2025 Oshima, Aisu, Masuo, Takakusagi and Kawai. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Targeting and monitoring cancer metabolism: novel theranostics for colorectal cancer

Nobu Oshima^{1,2*}, Yuki Aisu¹, Akihiko Masuo¹, Yoichi Takakusagi³ and Tatsuya Kawai⁴

¹Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Japan, ³Institute of Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan,

⁴Department of Radiology, Nagoya City University Hospital, Nagoya, Japan

KEYWORDS

cancer metabolism, glycolysis oxidative, phosphorylation, small molecules, imaging technology, 13C-MRI, clinical application

Editorial on the Research Topic

[Targeting and monitoring cancer metabolism: novel theranostics for colorectal cancer](#)

Colorectal cancer (CRC) remains a major global health burden, and there is increasing emphasis on understanding its metabolic landscape and identifying novel theranostic approaches. In recent years, hyperpolarized ¹³C-MRI, an innovative imaging technique that visualizes the metabolic characteristics of cancer tissue and treatment-induced metabolic changes, has been developed, leading to a surge in research reports on its applications. The advancement of scientific and technological approaches to understanding cancer metabolism has been remarkable, highlighting the rapid progress being made in this field. This Research Topic explores how cancer metabolism can be both targeted for therapy and monitored for disease progression, thereby advancing the field of personalized oncology. The five articles published in this Research Topic collectively make significant contributions to the understanding of metabolic reprogramming in CRC and its potential applications in clinical practice.

The first article, *Multi-omics analyses of glucose metabolic reprogramming in colorectal cancer* (Huang et al.), presents a comprehensive multi-omics approach to dissect the metabolic pathways underlying CRC progression. This study highlights how glucose metabolic reprogramming (GMR) is intricately linked to epithelial-mesenchymal transition (EMT) and metastatic potential. By integrating genomics, proteomics, and metabolomics data, the authors identify novel metabolic markers and propose the CEA/blood glucose ratio as a potential diagnostic tool for CRC liver metastasis.

The second article, *Development and validation of a risk prediction model for sarcopenia in patients with colorectal cancer* (Zhang and Zhu), addresses the often-overlooked issue of

sarcopenia in CRC patients. By constructing a predictive nomogram based on clinical and metabolic parameters, the study offers a valuable tool for the early identification of high-risk patients, enabling timely nutritional and therapeutic interventions to improve patient outcomes.

The third article, *Can proline dehydrogenase—a key enzyme involved in proline metabolism—be a novel target for cancer therapy?* (Xu et al.), explores the dual role of proline dehydrogenase (PRODH) in cancer metabolism. While PRODH can induce apoptosis through reactive oxygen species (ROS) signaling, it also promotes tumor survival under hypoxic conditions. This review provides an in-depth discussion of the potential of targeting PRODH as a novel therapeutic strategy for CRC.

The fourth article, *Fer governs mTORC1 regulating pathways and sustains the viability of pancreatic ductal adenocarcinoma cells* (Schrier et al.), investigates the regulatory role of the tyrosine kinase Fer in metabolic signaling pathways. Although the study primarily focuses on pancreatic ductal adenocarcinoma, its findings have broader implications for CRC. The study highlights how Fer-mediated regulation of mTORC1 activity influences cellular metabolism, paving the way for potential cross-cancer therapeutic applications.

Finally *The use of nutrigenomics and nutritional biomarkers with standard care of long-term recurrent metastatic rectal cancer: a case report* (Brinkman et al.), presents a compelling case study demonstrating the role of personalized nutrition in CRC management. By integrating nutrigenomics and monitoring key biomarkers such as folate, vitamin B12, and vitamin D, the study underscores the importance of a multidisciplinary approach to improve long-term patient survival.

Collectively, these articles underscore the evolving landscape of CRC research, emphasizing metabolic targeting and theranostics as essential components of personalized cancer therapy. From fundamental metabolic pathways to clinical applications, this Research Topic provides a foundation for future studies aimed at optimizing therapeutic strategies for CRC.

Regrettably, while this Research Topic provides numerous valuable topics of discussion and insight, it does not include a dedicated discourse on the application of hyperpolarized ¹³C-MRI. This imaging technique is a crucial element in the development of new cancer therapies, and further research is required to fully realize its potential applications. We look forward to future submissions that introduce novel imaging techniques and fresh perspectives on this technology.

We extend our sincere appreciation to all of the contributing authors, reviewers, and researchers who played a pivotal role in the development of this Research Topic. Their dedication and expertise have made it possible to advance the discourse in oncology, and we look forward to seeing how these findings inspire new research endeavors.

The corresponding author would also like to express gratitude to all contributors who have enriched this theme with their expertise and insights. Finally, thanks also go to co-editors, Professors Yoichi

Takakusagi and Tatsuya Kawai, along with Dr. Fuu Oshima, Professors Masayuki Matsuo, Fuminori Hyodo, Neckers Leonard and Murali C. Krishna for the fruitful discussion, Yukako Ito and Sayaka Sugiura for the administrative assistance.

Author contributions

NO: Writing – original draft, Writing – review & editing, Conceptualization, Funding acquisition, Project administration, Resources, Supervision. YA: Writing – review & editing. AM: Writing – review & editing. YT: Conceptualization, Resources, Writing – review & editing. TK: Conceptualization, Resources, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. This study received funding from the following sources: Grant Numbers: JP20K09054 and JP23K 08153, from The Ministry of Education, Culture, Sports, Science and Technology(MEXT) KAKENHI for Nobu Oshima (<https://www.mext.go.jp/index.htm>).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.